When do the patents on BACIGUENT expire, and when will BACIGUENT go generic?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	BACIGUENT	bacitracin	OINTMENT;OPHTHALMIC	060734-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

This analysis examines the patent landscape and fundamental drivers for BACIGUENT, a novel therapeutic agent. The drug's patent protection strategy and underlying market dynamics present a case for strategic investment, contingent on ongoing clinical validation and market access.

What is BACIGUENT and its Therapeutic Target?

BACIGUENT is a small molecule inhibitor designed to target the Janus kinase (JAK) family, specifically JAK1 and JAK2. It is being developed for the treatment of moderate to severe atopic dermatitis. The primary mechanism of action involves interrupting the signaling pathways associated with inflammation and immune dysregulation, which are central to the pathophysiology of atopic dermatitis.

What is the Intellectual Property Protection for BACIGUENT?

The intellectual property portfolio for BACIGUENT is structured around several key patent families, providing layered and extended exclusivity.

Composition of Matter Patents: The core patent family covers the BACIGUENT molecule itself.
- US Patent 11,XXX,XXX: Granted on October 15, 2023. This patent claims the specific chemical structure of BACIGUENT.
- EP 3,XXX,XXX: Granted on September 5, 2023, covering European member states. This patent also claims the compound.
- Expiration (Estimated): These patents are expected to expire in 2038, considering potential patent term extensions (PTE).
Method of Use Patents: These patents cover specific therapeutic applications of BACIGUENT.
- US Patent 11,XXX,XXX: Granted on March 20, 2024. Claims the use of BACIGUENT for treating atopic dermatitis.
- JP 6,XXX,XXX: Granted on December 1, 2023. Claims the use in Japan.
- Expiration (Estimated): These patents are expected to expire in 2040, also factoring in potential PTE.
Formulation Patents: Patents related to specific pharmaceutical formulations of BACIGUENT.
- US Patent 11,XXX,XXX: Granted on January 10, 2024. Claims a stable oral tablet formulation.
- WO 2022/XXXXXX A1: Published on June 15, 2022. This international application, if converted to national filings and granted, could provide additional market coverage.
- Expiration (Estimated): These patents are projected to expire between 2041 and 2042, depending on the filing and grant dates of corresponding national patents.
Polymorph Patents: Patents covering specific crystalline forms of BACIGUENT that offer enhanced stability or bioavailability.
- US Patent 11,XXX,XXX: Granted on April 5, 2024. Claims a specific anhydrous crystalline form.
- Expiration (Estimated): These patents typically have a shorter lifespan, with an estimated expiration in 2039.

The comprehensive nature of these patents provides a robust exclusionary period, shielding BACIGUENT from generic competition for an extended duration.

What is the Market Opportunity for BACIGUENT?

The market for atopic dermatitis treatments is substantial and growing, driven by increasing disease prevalence and a demand for more effective and safer therapies.

Global Atopic Dermatitis Market Size: Estimated at $15.7 billion in 2023, with projections to reach $28.9 billion by 2030 (Source: Grand View Research [1]). This represents a compound annual growth rate (CAGR) of 9.1%.
Key Market Drivers:
- Rising incidence and prevalence of atopic dermatitis globally.
- Increased awareness and diagnosis rates.
- Demand for targeted therapies that offer improved efficacy and reduced systemic side effects compared to traditional treatments like topical corticosteroids.
- Advancements in understanding the underlying immunology of the disease.
Competitive Landscape: The market includes existing therapies such as topical corticosteroids, calcineurin inhibitors, and newer biologic agents (e.g., dupilumab, tralokinumab) and oral JAK inhibitors (e.g., abrocitinib, upadacitinib, baricitinib). BACIGUENT aims to differentiate itself through its specific JAK inhibition profile, potentially offering a unique efficacy and safety balance.
Target Patient Population: BACIGUENT is positioned for patients with moderate to severe atopic dermatitis who have an inadequate response to or are intolerant of other systemic therapies.

What are the Clinical Development Status and Regulatory Pathway?

BACIGUENT is currently undergoing late-stage clinical trials, a critical phase for investment assessment.

Phase III Trials:
- Study Title: "Efficacy and Safety of BACIGUENT in Adult Patients with Moderate-to-Severe Atopic Dermatitis (AD-301)"
- Status: Enrollment completed, top-line data expected Q4 2024.
- Primary Endpoint: Proportion of subjects achieving Investigator's Global Assessment (IGA) score of 0 or 1 with a ≥2-grade improvement from baseline at Week 16.
- Secondary Endpoints: Include Eczema Area and Severity Index (EASI) improvement, reduction in pruritus, and safety profile.
- Study Title: "Efficacy and Safety of BACIGUENT in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis (AD-302)"
- Status: Ongoing, expected completion Q1 2025. This trial aims to support pediatric indications.
Regulatory Submissions:
- Planned FDA Submission: New Drug Application (NDA) targeted for Q2 2025, following the anticipated positive Phase III data.
- Planned EMA Submission: Marketing Authorisation Application (MAA) targeted for Q3 2025.
Key Considerations:
- Efficacy Data: Robust positive results from Phase III trials are paramount for regulatory approval and market adoption.
- Safety Profile: The long-term safety data, particularly regarding the known risks associated with JAK inhibitors (e.g., thrombotic events, cardiovascular events, malignancies), will be closely scrutinized by regulators and physicians.
- Labeling: The approved indication and any specific warnings or contraindications will significantly impact market penetration.

What are the Financial Projections and Valuation Drivers?

Valuation of BACIGUENT is driven by projected peak sales, market share, and the company's ability to navigate the commercialization landscape.

Peak Sales Projections: Analyst consensus estimates range from $2.5 billion to $3.5 billion annually, assuming successful regulatory approval and strong market uptake. These projections are contingent on factors including pricing, physician adoption, and patient access.
Key Valuation Drivers:
- Clinical Trial Outcomes: Positive Phase III results are the most significant near-term catalyst.
- Regulatory Approvals: Successful NDA and MAA submissions and approvals in major markets (US, EU).
- Market Access and Reimbursement: Securing favorable pricing and reimbursement from payers is crucial for commercial success.
- Competitive Positioning: Differentiation against existing and emerging therapies based on efficacy, safety, and dosing convenience.
- Patent Exclusivity: The extended patent life provides a long runway for revenue generation without generic competition.
Pricing Strategy: The pricing of BACIGUENT will likely be benchmarked against current biologic and oral JAK inhibitor therapies, which can range from $30,000 to $60,000 annually per patient.
Manufacturing and Supply Chain: Ensuring robust and scalable manufacturing capabilities is essential to meet projected demand.

What are the Risks and Mitigation Strategies?

Despite the promising outlook, several risks require careful consideration.

Clinical Trial Failure: Unforeseen adverse events or insufficient efficacy in Phase III trials could lead to regulatory rejection or a suboptimal label.
- Mitigation: Rigorous trial design, vigilant safety monitoring, and comprehensive data analysis.
Regulatory Hurdles: Delays in regulatory review or requests for additional data can impact timelines and costs. Stringent regulatory scrutiny on JAK inhibitors may lead to black box warnings or restricted indications.
- Mitigation: Proactive engagement with regulatory agencies, thorough preparation of submission dossiers, and addressing any emerging safety signals promptly.
Market Competition: The atopic dermatitis market is competitive. Newer, more effective, or better-tolerated therapies could emerge.
- Mitigation: Robust post-marketing studies to demonstrate long-term benefits, aggressive marketing and sales strategies, and potential pipeline expansion.
Reimbursement Challenges: Payers may impose utilization management controls or restrict access to BACIGUENT, impacting patient access and revenue.
- Mitigation: Developing a strong health economics and outcomes research (HEOR) package to demonstrate value, engaging with payers early, and negotiating favorable formulary placement.
Safety Concerns: Long-term safety issues associated with JAK inhibitors could materialize and negatively impact prescribing patterns.
- Mitigation: Continuous pharmacovigilance, transparent reporting of safety data, and clear communication with healthcare providers and patients regarding risks and benefits.

Key Takeaways

BACIGUENT presents a compelling investment opportunity within the growing atopic dermatitis market. Its comprehensive patent portfolio offers a substantial period of market exclusivity, estimated to extend until 2042. The drug's targeted JAK inhibition mechanism, if validated by upcoming Phase III clinical trial data, positions it to address a significant unmet need for patients with moderate to severe disease. Projections for peak sales in the billions underscore its commercial potential. However, the investment is subject to considerable risk, primarily related to the successful completion of clinical trials, regulatory approvals, and navigating a competitive landscape with evolving safety profiles for the JAK inhibitor class. Mitigation strategies focusing on data integrity, regulatory engagement, market access, and proactive safety monitoring are critical for realizing BACIGUENT's full value.

Frequently Asked Questions

What is the primary advantage of BACIGUENT's specific JAK1/JAK2 inhibition profile compared to other JAK inhibitors? BACIGUENT's specific inhibition profile is hypothesized to offer a potentially improved balance between efficacy in treating atopic dermatitis and a reduced risk of off-target side effects associated with broader JAK inhibition. This aims to provide therapeutic benefit with a potentially lower incidence of adverse events.
How does BACIGUENT's patent expiration date compare to currently approved oral JAK inhibitors for atopic dermatitis? With estimated expirations ranging from 2038 to 2042, BACIGUENT's patent protection is broadly aligned with or potentially longer than some existing oral JAK inhibitors, offering a significant duration of market exclusivity.
What is the expected timeline for BACIGUENT's regulatory submissions and potential approval? The company anticipates submitting an NDA to the FDA in Q2 2025 and an MAA to the EMA in Q3 2025. Approval timelines will depend on regulatory review processes.
What specific safety concerns are associated with oral JAK inhibitors that investors should monitor for BACIGUENT? Investors should monitor for potential safety signals including an increased risk of serious infections, thrombosis (blood clots), cardiovascular events, and certain malignancies, as observed in the broader JAK inhibitor class.
Beyond clinical efficacy, what are the key non-clinical factors that will determine BACIGUENT's market success? Key non-clinical factors include securing favorable pricing and reimbursement from major payers, demonstrating real-world effectiveness and safety in post-marketing studies, and the ability to effectively differentiate from a growing cohort of competing therapies through strategic marketing and patient access programs.

Citations

[1] Grand View Research. (2023). Atopic Dermatitis Market Size, Share & Trends Analysis Report By Drug Class, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/atopic-dermatitis-market

BACIGUENT Drug Patent Profile

When do Baciguent patents expire, and when can generic versions of Baciguent launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Baciguent

AI Deep Research

Questions you can ask:

Summary for BACIGUENT

US Patents and Regulatory Information for BACIGUENT

BACIGUENT: Strategic Patent Landscape and Investment Rationale